|
Name |
Globosuxanthone A
|
Molecular Formula | C15H12O7 | |
IUPAC Name* |
methyl (1R,2R)-1,2,8-trihydroxy-9-oxo-2H-xanthene-1-carboxylate
|
|
SMILES |
COC(=O)[C@@]1([C@@H](C=CC2=C1C(=O)C3=C(C=CC=C3O2)O)O)O
|
|
InChI |
InChI=1S/C15H12O7/c1-21-14(19)15(20)10(17)6-5-9-12(15)13(18)11-7(16)3-2-4-8(11)22-9/h2-6,10,16-17,20H,1H3/t10-,15+/m1/s1
|
|
InChIKey |
HEFOWMGZUBJFBY-BMIGLBTASA-N
|
|
Synonyms |
Globosuxanthone A; MLS004257380; CHEBI:68712; SMR003082512; HY-125727; CS-0093427; Q27137132; 1R*,2R*,8-trihydroxanthenone-1-carboxylic acid methyl ester; methyl (1R,2R)-1,2,8-trihydroxy-9-oxo-2H-xanthene-1-carboxylate; rel-methyl (1R,2R)-1,2,8-trihydroxy-9-oxo-2,9-dihydro-1H-xanthene-1-carboxylate
|
|
CAS | NA | |
PubChem CID | 16046111 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 304.25 | ALogp: | 1.1 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 113.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.662 |
Caco-2 Permeability: | -4.796 | MDCK Permeability: | 0.00001560 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.143 |
Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.125 |
Blood-Brain-Barrier Penetration (BBB): | 0.597 | Plasma Protein Binding (PPB): | 80.83% |
Volume Distribution (VD): | 0.961 | Fu: | 23.93% |
CYP1A2-inhibitor: | 0.383 | CYP1A2-substrate: | 0.938 |
CYP2C19-inhibitor: | 0.258 | CYP2C19-substrate: | 0.653 |
CYP2C9-inhibitor: | 0.183 | CYP2C9-substrate: | 0.357 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.216 |
CYP3A4-inhibitor: | 0.231 | CYP3A4-substrate: | 0.737 |
Clearance (CL): | 0.86 | Half-life (T1/2): | 0.794 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.819 |
Drug-inuced Liver Injury (DILI): | 0.971 | AMES Toxicity: | 0.614 |
Rat Oral Acute Toxicity: | 0.185 | Maximum Recommended Daily Dose: | 0.056 |
Skin Sensitization: | 0.336 | Carcinogencity: | 0.027 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.03 |
Respiratory Toxicity: | 0.046 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004884 | 1.000 | D0K8KX | 0.277 | ||||
ENC004138 | 0.718 | D0E3OF | 0.263 | ||||
ENC004286 | 0.627 | D07MGA | 0.260 | ||||
ENC004284 | 0.603 | D04AIT | 0.255 | ||||
ENC002954 | 0.603 | D06GCK | 0.252 | ||||
ENC004886 | 0.475 | D08QJS | 0.252 | ||||
ENC004885 | 0.468 | D0S0LZ | 0.252 | ||||
ENC002283 | 0.468 | D0H1AR | 0.252 | ||||
ENC004287 | 0.457 | D0J2NK | 0.248 | ||||
ENC002469 | 0.424 | D0Z3DY | 0.247 |